In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against other best mid-cap growth stocks to buy according to analysts. Investing in mid-cap ...

Legend Biotech (NASDAQ:LEGN – Get Free Report) had its target price dropped by analysts at Morgan Stanley from $82.00 to ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...

Despite initial caution, Carvykti's sales surged, reaching $334M in Q4 2024, driving Legend Biotech Corporation to net income and solidifying its market position. Legend's financial health is ...

5 analysts have shared their evaluations of Legend Biotech (NASDAQ:LEGN) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their ...

Caroline Paul; Associate Director of Investor Relations; Nanjing Legend Biotechnology Co Ltd Ying Huang; Chief Executive Officer; Nanjing Legend Biotechnology Co Ltd Jessie Yeung; Interim Chief ...

Legend Biotech Corporation (NASDAQ:LEGN), a $6.8 billion biotechnology company focused on developing novel cell therapies for oncology and other indications, has been garnering significant attention ...

SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ...

Legend Biotech Corporation (NASDAQ:LEGN), a $6.8 billion biotechnology company focused on developing novel cell therapies for oncology and other indications, has been garnering significant ...